Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
Novartis's Glivec recommended for adjuvant treatment of GIST in EU
23 March 2009
Malini Guha

mMalini.guha@informa.com

Novartis's Glivec (imatinib) has been recommended for EU approval by the CHMP for the adjuvant treatment of patients at significant risk of relapse following surgical removal of Kit-positive gastrointestinal stromal tumours (GIST).

Glivec is standard treatment in the EU and the US for the...



Please Login to read the full article.
 
Not a subscriber? Subscribe to Scrip Request a FREE Trial
RELATED CONTENT
NEWS Scrip News Other Informa News
ANALYSIS Scrip Analysis
COMMENT Scrip Comment Other Informa Comment
FEATURES Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK Promote your vacancy here
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm